Our company has been selected for AMED’s publicly funded project, advancing the development of manufacturing processes for tumor-infiltrating lymphocyte (TIL) regenerative medical products for cervical cancer. The research period is up to 3 years, with a subsidy of 92,300 thousand yen, aiming for early initiation of corporate clinical trials.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4978","jir_company_name":"G-ReproCell","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-07-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4978-20260724-01.pdf","jir_short_summary":"Our company has been selected for AMED's publicly funded project, advancing the development of manufacturing processes for tumor-infiltrating lymphocyte (TIL) regenerative medical products for cervical cancer. The research period is up to 3 years, with a subsidy of 92,300 thousand yen, aiming for early initiation of corporate clinical trials.","jir_summary":"### Overview of Research and Development\nOur company has been selected for the AMED renewal medicine and gene therapy industry initiative to develop foundational technologies, specifically for manufacturing process development of TIL regenerative medical products for cervical cancer. The research will be conducted over a maximum of 3 years, with a planned subsidy of 92,300 thousand yen. TIL therapy involves culturing the patient's own immune cells to attack cancer, an individualized immunotherapy already confirmed safe and tolerable domestically. Moving forward, we will develop commercially compliant manufacturing processes and quality assurance systems to enable early initiation of corporate trials.\n\n### Future Outlook and Corporate Initiatives\nSuccessful completion of this project will strengthen our company's manufacturing and supply system for TIL therapy and promote clinical application both domestically and internationally. Clinical trials for cervical cancer using TIL therapy are also underway in the United States, and future expansion of treatment options is expected depending on clinical outcomes. As the research progresses and final subsidy amounts are confirmed, we will clarify specific business development plans and revenue prospects.","jir_financial_highlights":"Subsidy-Eligible Expenses: 92,300 thousand yen (Unknown)\nResearch Implementation Period: Up to 3 years (FY 2026 to FY 2028) (Unknown)","jir_category":"","jir_hashtags":"#ReproCell, #IRRelated, #JapaneseStocks","jir_key_figures":"Subsidy-Eligible Expenses: 92,300 thousand yen (planned)\nResearch Period: Up to 3 years (FY 2026 to FY 2028)\nSelection Date: July 24, 2026","jir_meta_title":"\u3010ReproCell\u3011Cervical Cancer Immunotherapy Research Selected\uff5cJuly 2026","jir_meta_description":"ReproCell has been selected for AMED's research and development project, advancing manufacturing process development for cervical cancer TIL therapy. The research period is 3 years, with a subsidy of 92,300 thousand yen.","jir_og_title":"\u3010ReproCell\u3011Cervical Cancer Immunotherapy Research Selected\uff5cJuly 2026","jir_og_description":"ReproCell has been selected for research and development of cervical cancer immunotherapy, aiming for future clinical application. The research period is 3 years, with a subsidy of 92,300 thousand yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58459,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-88269","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n